Company Encyclopedia
View More
name
Zhongxing BioTech
002772.SZ
Tianshui Zhongxing Bio-technology Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of edible fungi in China and internationally. It offers flammulina velutipe mushrooms under the Xihuang brand; agaricus bisporus mushrooms under the Zhongxing brand; and cordyceps sinensis mushrooms, as well as packaging boxes for its products. The company also engages in agriculture planting, investment management, and real estate development businesses. Tianshui Zhongxing Bio-technology Co.,Ltd.
2.134 T
002772.SZMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
Packaged Foods and MeatsIndustry
Industry Ranking90/137
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.17%B
    • Profit Margin12.22%B
    • Gross Margin34.56%C
  • Growth ScoreB
    • Revenue YoY5.23%C
    • Net Profit YoY235.22%A
    • Total Assets YoY3.90%C
    • Net Assets YoY-0.16%C
  • Cash ScoreC
    • Cash Flow Margin818.18%B
    • OCF YoY5.23%C
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreC
    • Gearing Ratio48.13%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhongxing BioTech released its performance for the first three quarters, with a net profit attributable to the parent company of 204 million yuan, a year-on-year increase of 130.51%

    According to the Zhitong Finance APP, Zhongxing BioTech released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.475 billion yuan, a year-on-year increase of 4.16%. The net profit attributable to shareholders of the listed company was 204 million yuan, a year-on-year increase of 130.51%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 184 million yuan, a year-on-year increase of 181.09%

    Zhitong·
    SZ
    002772
    +1.02%
    Zhitong·
    SZ
    002772
    +1.02%

    Zhongxing BioTech provides guarantees for its subsidiaries, with a cumulative guarantee balance exceeding 1.1 billion yuan

    Zhongxing BioTech announced on October 16, 2025, that it would provide a guarantee limit of no more than 1.97 billion yuan for certain wholly-owned subsidiaries. To meet funding needs, Jiangsu Zhongxing applied for a loan of 350 million yuan from Jiangsu Bank, and Zhongxing BioTech provided a joint liability guarantee for it; Hubei Zhongxing applied for a loan of no more than 40 million yuan from China Construction Bank, and Zhongxing BioTech also provided a guarantee. As of the announcement date, the total guarantee balance for subsidiaries within the scope of the consolidated financial statements was 1.152 billion yuan, accounting for 34.73% of the net assets for the fiscal year 2024

    Zhitong·
    SZ
    002772
    +1.02%
    Zhitong·
    SZ
    002772
    +1.02%

    Zhongxing BioTech plans to launch a stock option incentive plan for 14.375 million shares

    According to the Zhitong Finance APP, Zhongxing BioTech disclosed its 2025 stock option incentive plan (draft), proposing to grant a total of 14.375 million stock options to the incentive recipients, accounting for approximately 3.66% of the company's total equity at the time of the announcement of the incentive plan draft. Among them, 11.5 million options will be granted initially, with a total of 17 recipients for the initial grant, and the exercise price is set at 6.87 yuan per share

    Zhitong·
    SZ
    002772
    +1.02%
    Zhitong·
    SZ
    002772
    +1.02%

    Zhongxing BioTech: Recently, there have been no significant changes in the company's operating conditions or the internal and external operating environment

    Zhongxing BioTech announced on September 14th that there have been no significant changes in the company's operating conditions and internal and external business environment recently. The cumulative price deviation of the company's stock closing price has exceeded 20% over three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. After verification, it was confirmed that there is no need to correct or supplement the previously disclosed information, and no undisclosed significant information that could affect the stock trading price has been found. Internal production and business activities are normal, and the controlling shareholder and actual controller did not buy or sell the company's stock during the period of abnormal fluctuation

    Zhitong·
    SZ
    002772
    +1.02%
    Zhitong·
    SZ
    002772
    +1.02%

    Zhongxing BioTech: Net profit in the first half of the year is expected to increase by 86.57%-137.46% year-on-year

    Zhongxing BioTech released its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 55 million yuan and 70 million yuan, an increase of 86.57% to 137.46% compared to the same period last year. During the reporting period, the sales price of Agaricus bisporus products remained stable with an upward trend, and the operating performance of individual products increased year-on-year; investment income from joint ventures increased year-on-year; investment income from financial products and changes in fair value gains and losses increased by approximately 8 million yuan year-on-year; financial expenses decreased year-on-year

    Zhitong·
    SZ
    002772
    +1.02%
    Zhitong·
    SZ
    002772
    +1.02%
    © 2025 Longbridge｜Disclaimer